
51 - 200 employees
Founded 2019
🧬 Biotechnology
đź’Š Pharmaceuticals
🔬 Science
đź’° $85M Series B on 2022-01
Biotechnology • Pharmaceuticals • Science
Kyverna Therapeutics is a patient-centered, clinical-stage biopharmaceutical company focused on developing cell therapies for patients suffering from autoimmune diseases. The company is pioneering CAR T-cell therapies, leveraging the transformational power of T cells to potentially provide sustained, treatment-free remission for autoimmune conditions. Kyverna's lead CAR T-cell therapy candidate, KYV-101, is advancing through clinical trials targeting various autoimmune diseases, including multiple sclerosis, myasthenia gravis, systemic sclerosis, and lupus nephritis. Their pipeline features innovative chimeric antigen receptor (CAR) T-cell therapies in both autologous and allogeneic formats aimed at B cell-driven autoimmune diseases.
đź•’ July 8
Improve your chances of getting an interview by checking your resume score before you apply.

51 - 200 employees
Founded 2019
🧬 Biotechnology
đź’Š Pharmaceuticals
🔬 Science
đź’° $85M Series B on 2022-01
Biotechnology • Pharmaceuticals • Science
Kyverna Therapeutics is a patient-centered, clinical-stage biopharmaceutical company focused on developing cell therapies for patients suffering from autoimmune diseases. The company is pioneering CAR T-cell therapies, leveraging the transformational power of T cells to potentially provide sustained, treatment-free remission for autoimmune conditions. Kyverna's lead CAR T-cell therapy candidate, KYV-101, is advancing through clinical trials targeting various autoimmune diseases, including multiple sclerosis, myasthenia gravis, systemic sclerosis, and lupus nephritis. Their pipeline features innovative chimeric antigen receptor (CAR) T-cell therapies in both autologous and allogeneic formats aimed at B cell-driven autoimmune diseases.
• Provide strategic and operational regulatory leadership across Kyverna's cell therapy portfolio, with a focus on commercial readiness, labeling strategy, and health authority engagement. • Define and execute global regulatory strategy to support clinical development, registration, and commercialization of Kyverna's autoimmune cell therapies. • Translate scientific and clinical data into approvable, commercially viable labeling and lead interactions with regulatory authorities, including FDA and global counterparts. • Lead global regulatory strategy for Kyverna's development programs, aligning clinical, CMC, and commercial objectives from early development through post-approval lifecycle management. • Provide regulatory input to program governance, asset prioritization, and portfolio decisions, including scenario planning and risk mitigation. • Anticipate and address regulatory challenges related to cell therapy development, manufacturing, comparability, and long-term follow-up. • Serve as the primary senior regulatory interface with FDA, EMA, and other global health authorities. • Lead and/or support key regulatory meetings, including INTERACT, pre-IND, End-of-Phase, pre-BLA/MAA, Advisory Committees, and post-marketing commitments. • Drive regulatory negotiation strategy, including benefit-risk, endpoints, comparability, and post-approval requirements. • Own and drive labeling strategy from early development through approval, ensuring labels support commercial differentiation, patient access, and lifecycle value. • Lead development of Target Product Profiles (TPPs) and ensure alignment across Clinical, Regulatory, Commercial, and Market Access. • Partner with Commercial, Medical Affairs, and Market Access to ensure regulatory decisions support launch readiness, promotional strategy, and payer engagement. • Lead label negotiations with health authorities, balancing scientific evidence, regulatory expectations, and commercial objectives. • Oversee and contribute to the preparation, review, and submission of INDs, CTAs, BLAs/MAAs, briefing packages, orphan drug applications, and other regulatory filings. • Ensure submissions are high-quality, compliant, and strategically positioned. • Maintain oversight of submission timelines, dependencies, and risk management, providing clear communication to senior leadership. • Act as a strategic partner to Clinical Development, CMC, Research, Commercial, Legal, BD, and Alliance Management teams. • Provide regulatory due diligence and strategic input for business development, in-licensing, out-licensing, and partnership opportunities. • Oversee regulatory activities performed by CROs, consultants, and partners, ensuring quality and strategic alignment. • Lead, mentor, and scale a high-performing regulatory team, fostering accountability, development, and a culture of collaboration. • Establish and maintain regulatory policies, procedures, and infrastructure to support a growing, late-stage organization. • Stay current on US and global regulatory intelligence and communicate key implications to stakeholders.
• Bachelor's degree in a scientific discipline required; advanced degree preferred. • 15+ years of progressive regulatory affairs experience in pharmaceutical or biotechnology, with significant advanced therapy experience. • Cell and/or gene therapy experience preferred; autoimmune disease experience highly preferred. • Demonstrated success leading global regulatory strategies through late-stage development and/or approvals, ideally including BLA/MAA experience. • Proven experience with labeling strategy development and negotiation, with strong understanding of commercialization impacts. • Deep knowledge of FDA regulations, ICH guidelines, and global regulatory frameworks; EMA and ex-US experience preferred. • Track record of effective engagement with FDA OTP and/or divisions overseeing autoimmune or immune-mediated diseases. • Strong executive communication skills with the ability to influence senior leadership and Board-facing audiences. • Demonstrated ability to lead and scale teams in a fast-paced, high-growth environment. Prior supervisory experience preferred. • Strategic mindset with the ability to balance scientific rigor, regulatory compliance, and commercial impact.
• bonus • benefits • participation in the company's stock plan
Apply Nowđź•’ July 8
Corporate Governance, Risk, and Compliance Analyst at Onebrief managing RMF, CMMC, and SOC 2 compliance. Collaborating with various teams to ensure adherence to federal and corporate regulations.
🇺🇸 United States – Remote
đź’µ $160k - $200k / year
đź’° $21M Venture Round on 2022-10
⏰ Full Time
đźź Senior
đź”´ Lead
đźš” Compliance
đź•’ July 8
Manager, Compliance supporting the Chief Compliance Officer in ensuring adherence to healthcare compliance standards. Develops initiatives, manages audits, and leads compliance investigations.
đź•’ July 7
Vice President of Regulatory Affairs developing global strategies for innovative therapeutics and devices at Contraline. Leading regulatory processes from preclinical stages to commercialization as a senior regulatory leader.
đź•’ July 7
Head of Risk & Compliance overseeing regulatory and fraud strategies at Collectors' service. Leading compliance programs and risk frameworks across multiple business units.
🇺🇸 United States – Remote
đź’µ $197.2k - $280.1k / year
⏰ Full Time
đź”´ Lead
đźš” Compliance
🦅 H1B Visa Sponsor
đź•’ July 6
Quality Systems & Regulatory Affairs leader at CEFALY Technology ensuring compliance and audit readiness across quality systems. Focus on QMS optimization and regulatory affairs for medical devices.
🇺🇸 United States – Remote
đź’µ $160k - $180k / year
đź’° Private Equity Round on 2019-08
⏰ Full Time
đź”´ Lead
đźš” Compliance